PubMed@dpavot:32876196_en_relations JSON TXT

Annnotations TAB JSON ListView MergeView

ENG_RE

{"project":"ENG_RE","denotations":[{"id":"T0","span":{"begin":26,"end":29},"obj":"CHEBI_33697"},{"id":"T1","span":{"begin":54,"end":60},"obj":"HP_0012828"},{"id":"T2","span":{"begin":61,"end":66},"obj":"HP_0011009"},{"id":"T3","span":{"begin":79,"end":86},"obj":"DOID_4"},{"id":"T4","span":{"begin":96,"end":104},"obj":"DOID_0080600"},{"id":"T5","span":{"begin":115,"end":123},"obj":"DOID_0080600"},{"id":"T6","span":{"begin":153,"end":160},"obj":"DOID_4"},{"id":"T7","span":{"begin":181,"end":187},"obj":"HP_0012828"},{"id":"T8","span":{"begin":248,"end":257},"obj":"GO_0009058"},{"id":"T9","span":{"begin":383,"end":391},"obj":"DOID_0080600"},{"id":"T10","span":{"begin":593,"end":601},"obj":"DOID_0080600"},{"id":"T11","span":{"begin":1093,"end":1101},"obj":"CHEBI_16919"},{"id":"T12","span":{"begin":1202,"end":1222},"obj":"DOID_0080600"},{"id":"T13","span":{"begin":1332,"end":1340},"obj":"DOID_0080600"},{"id":"T14","span":{"begin":1356,"end":1361},"obj":"HP_0011009"},{"id":"T15","span":{"begin":1424,"end":1444},"obj":"DOID_0080600"}],"relations":[{"id":"R17","pred":"effect","subj":"T15","obj":"T0"},{"id":"R18","pred":"no_relation","subj":"T15","obj":"T11"},{"id":"R0","pred":"no_relation","subj":"T8","obj":"T1"},{"id":"R1","pred":"no_relation","subj":"T8","obj":"T7"},{"id":"R2","pred":"effect","subj":"T8","obj":"T14"},{"id":"R3","pred":"effect","subj":"T3","obj":"T0"},{"id":"R4","pred":"effect","subj":"T3","obj":"T11"},{"id":"R5","pred":"no_relation","subj":"T4","obj":"T0"},{"id":"R6","pred":"no_relation","subj":"T4","obj":"T11"},{"id":"R7","pred":"no_relation","subj":"T5","obj":"T0"},{"id":"R8","pred":"no_relation","subj":"T5","obj":"T11"},{"id":"R9","pred":"no_relation","subj":"T6","obj":"T0"},{"id":"R10","pred":"no_relation","subj":"T6","obj":"T11"},{"id":"R11","pred":"effect","subj":"T9","obj":"T0"},{"id":"R12","pred":"no_relation","subj":"T10","obj":"T0"},{"id":"R13","pred":"effect","subj":"T12","obj":"T0"},{"id":"R14","pred":"no_relation","subj":"T12","obj":"T11"},{"id":"R15","pred":"effect","subj":"T13","obj":"T0"},{"id":"R16","pred":"no_relation","subj":"T13","obj":"T11"}],"text":"SARS-CoV-2 is an emerging RNA virus associated with a severe acute respiratory disease known as COVID-19. Although COVID-19 is predominantly a pulmonary disease, some patients have severe cardiovascular damage. We performed a quantitative evidence synthesis of clinical data, myocardial injury biomarkers, and cardiac complications associated with in-hospital death in patients with COVID-19.We searched the databases PubMed, Embase, and Google Scholar to identify studies comparing clinical data, myocardial injury biomarkers, and cardiac complications between non-survivors and survivors of COVID-19. Effect sizes were reported as mean difference or standardized mean difference for continuous variables and risk ratio for dichotomous variables with 95% confidence intervals. A random effects model was used to pool the results.Six retrospective studies reporting data from 1,141 patients (832 survivors and 309 non-survivors) were included. We found that underlying cardiovascular conditions; elevation of high-sensitivity cardiac troponin I, N-terminal pro-B-type natriuretic peptide, and creatine kinase-MB; and cardiac complications were associated with increased risk of death for patients with SARS-CoV-2 infection.The confirmation that underlying cardiovascular conditions, elevation of myocardial injury biomarkers during COVID-19 infection, and acute cardiovascular decompensation are predictors for mortality in SARS-CoV-2 infection must encourage new research to clarify potential mechanisms and test appropriate treatments. (Arq Bras Cardiol. 2020; 115(2):273-277)."}

RELASIGEBLAH7hhaider5

ENG_RE_Diana

{"project":"ENG_RE_Diana","denotations":[{"id":"T0","span":{"begin":26,"end":29},"obj":"CHEBI_33697"},{"id":"T1","span":{"begin":54,"end":60},"obj":"HP_0012828"},{"id":"T10","span":{"begin":593,"end":601},"obj":"DOID_0080600"},{"id":"T11","span":{"begin":1093,"end":1101},"obj":"CHEBI_16919"},{"id":"T12","span":{"begin":1202,"end":1222},"obj":"DOID_0080600"},{"id":"T13","span":{"begin":1332,"end":1340},"obj":"DOID_0080600"},{"id":"T14","span":{"begin":1356,"end":1361},"obj":"HP_0011009"},{"id":"T15","span":{"begin":1424,"end":1444},"obj":"DOID_0080600"},{"id":"T2","span":{"begin":61,"end":66},"obj":"HP_0011009"},{"id":"T3","span":{"begin":79,"end":86},"obj":"DOID_4"},{"id":"T4","span":{"begin":96,"end":104},"obj":"DOID_0080600"},{"id":"T5","span":{"begin":115,"end":123},"obj":"DOID_0080600"},{"id":"T6","span":{"begin":153,"end":160},"obj":"DOID_4"},{"id":"T7","span":{"begin":181,"end":187},"obj":"HP_0012828"},{"id":"T9","span":{"begin":383,"end":391},"obj":"DOID_0080600"}],"relations":[{"id":"R10","pred":"no_relation","subj":"T6","obj":"T11"},{"id":"R11","pred":"effect","subj":"T9","obj":"T0"},{"id":"R12","pred":"no_relation","subj":"T10","obj":"T0"},{"id":"R13","pred":"effect","subj":"T12","obj":"T0"},{"id":"R14","pred":"effect","subj":"T12","obj":"T11"},{"id":"R15","pred":"effect","subj":"T13","obj":"T0"},{"id":"R16","pred":"effect","subj":"T13","obj":"T11"},{"id":"R17","pred":"effect","subj":"T15","obj":"T0"},{"id":"R18","pred":"effect","subj":"T15","obj":"T11"},{"id":"R3","pred":"effect","subj":"T3","obj":"T0"},{"id":"R4","pred":"effect","subj":"T3","obj":"T11"},{"id":"R5","pred":"effect","subj":"T4","obj":"T0"},{"id":"R6","pred":"effect","subj":"T4","obj":"T11"},{"id":"R7","pred":"no_relation","subj":"T5","obj":"T0"},{"id":"R8","pred":"effect","subj":"T5","obj":"T11"},{"id":"R9","pred":"no_relation","subj":"T6","obj":"T0"},{"id":"R19","pred":"effect","subj":"T14","obj":"T15"}],"text":"SARS-CoV-2 is an emerging RNA virus associated with a severe acute respiratory disease known as COVID-19. Although COVID-19 is predominantly a pulmonary disease, some patients have severe cardiovascular damage. We performed a quantitative evidence synthesis of clinical data, myocardial injury biomarkers, and cardiac complications associated with in-hospital death in patients with COVID-19.We searched the databases PubMed, Embase, and Google Scholar to identify studies comparing clinical data, myocardial injury biomarkers, and cardiac complications between non-survivors and survivors of COVID-19. Effect sizes were reported as mean difference or standardized mean difference for continuous variables and risk ratio for dichotomous variables with 95% confidence intervals. A random effects model was used to pool the results.Six retrospective studies reporting data from 1,141 patients (832 survivors and 309 non-survivors) were included. We found that underlying cardiovascular conditions; elevation of high-sensitivity cardiac troponin I, N-terminal pro-B-type natriuretic peptide, and creatine kinase-MB; and cardiac complications were associated with increased risk of death for patients with SARS-CoV-2 infection.The confirmation that underlying cardiovascular conditions, elevation of myocardial injury biomarkers during COVID-19 infection, and acute cardiovascular decompensation are predictors for mortality in SARS-CoV-2 infection must encourage new research to clarify potential mechanisms and test appropriate treatments. (Arq Bras Cardiol. 2020; 115(2):273-277)."}

ENG_RE_pruas

ENG_RE_mabarros

{"project":"ENG_RE_mabarros","denotations":[{"id":"T0","span":{"begin":26,"end":29},"obj":"CHEBI_33697"},{"id":"T1","span":{"begin":54,"end":60},"obj":"HP_0012828"},{"id":"T10","span":{"begin":593,"end":601},"obj":"DOID_0080600"},{"id":"T11","span":{"begin":1093,"end":1101},"obj":"CHEBI_16919"},{"id":"T12","span":{"begin":1202,"end":1222},"obj":"DOID_0080600"},{"id":"T13","span":{"begin":1332,"end":1340},"obj":"DOID_0080600"},{"id":"T14","span":{"begin":1356,"end":1361},"obj":"HP_0011009"},{"id":"T15","span":{"begin":1424,"end":1444},"obj":"DOID_0080600"},{"id":"T2","span":{"begin":61,"end":66},"obj":"HP_0011009"},{"id":"T3","span":{"begin":79,"end":86},"obj":"DOID_4"},{"id":"T4","span":{"begin":96,"end":104},"obj":"DOID_0080600"},{"id":"T5","span":{"begin":115,"end":123},"obj":"DOID_0080600"},{"id":"T6","span":{"begin":153,"end":160},"obj":"DOID_4"},{"id":"T7","span":{"begin":181,"end":187},"obj":"HP_0012828"},{"id":"T9","span":{"begin":383,"end":391},"obj":"DOID_0080600"}],"relations":[{"id":"R7","pred":"no_relation","subj":"T5","obj":"T0"},{"id":"R8","pred":"no_relation","subj":"T5","obj":"T11"},{"id":"R9","pred":"no_relation","subj":"T6","obj":"T0"},{"id":"R10","pred":"no_relation","subj":"T6","obj":"T11"},{"id":"R11","pred":"effect","subj":"T9","obj":"T0"},{"id":"R12","pred":"no_relation","subj":"T10","obj":"T0"},{"id":"R13","pred":"effect","subj":"T12","obj":"T0"},{"id":"R14","pred":"no_relation","subj":"T12","obj":"T11"},{"id":"R15","pred":"effect","subj":"T13","obj":"T0"},{"id":"R16","pred":"no_relation","subj":"T13","obj":"T11"},{"id":"R17","pred":"effect","subj":"T15","obj":"T0"},{"id":"R18","pred":"no_relation","subj":"T15","obj":"T11"},{"id":"R4","pred":"effect","subj":"T3","obj":"T11"},{"id":"R5","pred":"no_relation","subj":"T4","obj":"T0"},{"id":"R6","pred":"no_relation","subj":"T4","obj":"T11"}],"text":"SARS-CoV-2 is an emerging RNA virus associated with a severe acute respiratory disease known as COVID-19. Although COVID-19 is predominantly a pulmonary disease, some patients have severe cardiovascular damage. We performed a quantitative evidence synthesis of clinical data, myocardial injury biomarkers, and cardiac complications associated with in-hospital death in patients with COVID-19.We searched the databases PubMed, Embase, and Google Scholar to identify studies comparing clinical data, myocardial injury biomarkers, and cardiac complications between non-survivors and survivors of COVID-19. Effect sizes were reported as mean difference or standardized mean difference for continuous variables and risk ratio for dichotomous variables with 95% confidence intervals. A random effects model was used to pool the results.Six retrospective studies reporting data from 1,141 patients (832 survivors and 309 non-survivors) were included. We found that underlying cardiovascular conditions; elevation of high-sensitivity cardiac troponin I, N-terminal pro-B-type natriuretic peptide, and creatine kinase-MB; and cardiac complications were associated with increased risk of death for patients with SARS-CoV-2 infection.The confirmation that underlying cardiovascular conditions, elevation of myocardial injury biomarkers during COVID-19 infection, and acute cardiovascular decompensation are predictors for mortality in SARS-CoV-2 infection must encourage new research to clarify potential mechanisms and test appropriate treatments. (Arq Bras Cardiol. 2020; 115(2):273-277)."}